NeurologyLive® Mind Moments®

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.In this episode, "Key Challenges Facing Neurology in the Year Ahead," Natalia Rost, MD, President of the American Academy of Neurology (AAN), Stroke Division Chief at Massachusetts General Hospital, and Professor of Neurology at Harvard Medical School, joins NeurologyLive to discuss the top clinical priorities shaping neurology in 2026.Throughout the discussion, Rost outlines the most urgent unmet needs across neurology, including expanding equitable access to care, integrating preventive neurology into routine practice, strengthening the workforce, and closing persistent evidence gaps. She explains how the AAN Brain Health Initiative provides a practical framework for embedding brain health into everyday clinical encounters. The conversation also explores the growing role of biomarkers, imaging, and digital tools in care delivery, where innovation may be outpacing evidence, and how the Academy aims to guide ethical and evidence based implementation while addressing ongoing health equity gaps.Episode Breakdown: 1:10 – Most urgent unmet clinical needs facing neurology in 2026 3:25 – Implementing brain health in everyday clinical practice 8:00 – Role of biomarkers, imaging, and digital tools in routine neurologic care 11:20 – AAN priorities for education, advocacy, and clinical guidance in 2026 14:25 – Major clinical gaps driving health inequities in neurologic care and outcomes Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Amaal Starling, MD, FAHS, FAAN, joins the podcast to provide clinical perspective on the INFUSE real world study evaluating IV eptinezumab in adults with migraine who previously found one or more CGRP preventive options ineffective, based on data presented at the 2026 Headache Cooperative of the Pacific Annual Conference. Starling, an associate professor of neurology at Mayo Clinic College of Medicine and a study author on INFUSE, discusses how clinicians should interpret the magnitude of benefit in a high burden population and why IV delivery, including rapid and consistent bioavailability, may help explain early and sustained response. The conversation also explores what the findings suggest for real world care and treatment sequencing, how migraine trials can better capture patient experience through outcomes like good days and PGIC, and what precision medicine research could look like next as the field pushes toward predictive modeling and individualized treatment selection.Looking for more Headache & Migraine discussion? Check out the NeurologyLive® Headache & Migraine clinical focus page.Episode Breakdown: 1:20 – Interpreting real world response after prior CGRP preventive failure 4:25 – Mechanistic reasons IV eptinezumab may drive early sustained benefit 6:25 – Clinical implications for earlier, more robust treatment sequencing 8:50 – Neurology News Network  11:20 – Integrating good days and Patient Global Impression scales into migraine trial design 15:30 – Future studies needed to advance precision migraine care The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Fenebrutinib Achieves Primary End Point in Phase 3 Head-to-Head Trial vs Teriflunomide in Relapsing MS Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies Efgartigimod Meets Primary End Point in Phase 3 ADAPT OCULUS Study of Ocular Myasthenia Gravis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this special Mind Moments episode, Lauren Sansing, MD, MS, FAHA, FANA, Professor of Neurology at Yale School of Medicine, joins the podcast to provide a clinical breakdown of the 2026 International Stroke Conference and its implications for real-world stroke care. Sansing reflects on how this year’s meeting built on prior advances, highlighting expanded global collaboration, greater patient engagement, and a record number of clinical trials presented. The discussion explores which late-breaking studies may influence practice in the coming year, including data on secondary stroke prevention, adjunctive thrombolysis strategies, and evolving patient selection for thrombectomy in extended windows and large core infarcts. Sansing also reviews renewed momentum in neuroprotection research, key updates from the newly released acute ischemic stroke guidelines, emerging pediatric stroke data, and how the conference continues to shape the roadmap for 2027 and beyond.Looking for more Stroke discussion? Check out the NeurologyLive® Stroke clinical focus page.Episode Breakdown: 1:00 – Biggest moments and structural evolution of ISC 2026 3:15 – Presented practice-changing trial data impacting stroke care 7:05 – Thrombectomy strategy and extended window patient selection 10:40 – Renewed momentum in neuroprotection research 15:20 – Neurology News Network  17:40 – Key updates from the new acute ischemic stroke guidelines 25:00 – A brief look-ahead to ISC 2027 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: PTC Withdraws Ataluren Submission as Treatment for Nonsense Mutation Duchenne Muscular Dystrophy Microbiome-Targeted Agent PLL001 Passes Safety Check in Phase 1/2 Trial of ALS Rimegepant Displays Safety and Efficacy in Study of Adolescents With Migraine Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Jeff Chamberlain, PhD, joins the podcast during Duchenne Muscular Dystrophy Awareness Week to provide clinical and translational perspective on the evolving landscape of DMD biology and therapy. Chamberlain, professor at the University of Washington School of Medicine and Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center in Seattle, reflects on aspects of Duchenne pathophysiology that may still be underappreciated, including evidence that disease processes begin earlier than once recognized and the growing importance of immunologic factors in shaping progression and therapeutic response. The conversation also explores how neuromuscular specialists should approach treatment timing and combination strategies as gene-targeted therapies expand, the evolving interpretation and limitations of biomarkers such as creatine kinase and dystrophin expression, and what emerging gene therapy platforms may signal for care heading into 2026 and beyond.Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.Episode Breakdown: 1:15 – Underrecognized aspects of DMD pathophysiology, including early onset and immunologic drivers 4:50 – Treatment timing, sequencing, and the rationale for combination strategies 8:00 – Neurology News Minute 10:30 – Clinical trial and real-world implications of dystrophin and CK as biomarkers 16:20 – Anticipated gene therapy innovation and safety considerations heading into 2026 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review FDA Expands Indication for Pitolisant to Treat Cataplexy in Pediatric Narcolepsy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.In this special edition of Mind Moments, Shyam Prabhakaran, MD, MS, the James Nelson and Anna Louise Raymond Professor of Neurology and chair of the Department of Neurology at the University of Chicago Medicine, joined the show to discuss the recent updates to the American Heart Association/American Stroke Association's guideline for the early management of acute ischemic stroke.  Prabhakaran clarified the main takeaways for clinicians and touched on details around endovascular thrombectomy care in pediatrics as well as treatment within and outside of the golden window.For NeurologyLive's coverage of ISC 2026, head here: International Stroke Conference (ISC) To read the new guidelines, head here: 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke AssociationThanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Benjamin Tolchin, MD, MS, FAAN, joins the podcast to provide clinical perspective on the recently published American Academy of Neurology (AAN) guidelines on functional seizures, drawing on his role as a contributing author to the recommendations. Tolchin, Director of the Center for Clinical Ethics at Yale New Haven Health and Associate Professor of Neurology at Yale School of Medicine, discusses what prompted the development of the first AAN guideline in this space and how the evidence base evolved to support formal recommendations. The conversation explores key considerations around diagnosing functional seizures, including history, semiology, EEG use, and the growing role of video documentation. Tolchin also addresses how clinicians should approach psychiatric comorbidities and co-occurring epilepsy, the evidence supporting psychological interventions, why pharmacologic therapies are not recommended for functional seizures themselves, and where major gaps remain in research to advance care in the years ahead.Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.Episode Breakdown: 1:10 – Why growing evidence prompted the first AAN guideline on functional seizures 3:20 – Diagnostic priorities including history, semiology, EEG, and video documentation 6:15 – Assessing psychiatric comorbidities and co-occurring epilepsy in functional seizures 9:15 – Neurology News Minute 11:30 – Evidence supporting psychotherapy for functional seizures 14:50 – Pharmacological evidence and use of antiseizure medications for functional seizures 18:35 – Barriers to advancing clinical trials in functional seizures 22:05 – Research priorities to refine treatment and long-term outcomes The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Subcutaneous Copper Histidinate as First Treatment for Pediatric Menkes Disease sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis High-Dose Nusinersen Gains European Commission Approval for Spinal Muscular Atrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, "Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies," Johannes Streffer, MD, PhD, discusses phase 1/2 findings from the PACIFIC trial evaluating bexicaserin in developmental epileptic encephalopathies, presented at the American Epilepsy Society 2025 Annual Meeting. Streffer, senior vice president of clinical development at Lundbeck, outlines the scientific and clinical rationale for studying DEEs as a unified population, emphasizing the unmet need and complexity of trial design in this highly vulnerable group. He reviews key efficacy outcomes, including sustained reductions in countable motor seizures and strong patient retention through long-term open-label extension and expanded access follow-up. The discussion also explores safety and tolerability considerations in patients receiving multiple concomitant antiseizure medications, the highly selective mechanism of action of bexicaserin, and how Lundbeck’s broader strategy in rare neurological disorders aims to de-risk development early while addressing populations with limited therapeutic options.Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.Episode Breakdown: 1:05 – Rationale for studying developmental epileptic encephalopathies as a unified group 3:05 – Challenges of trial design and retention in vulnerable pediatric DEE populations 5:25 – Key PACIFIC efficacy findings and long-term open-label extension results 7:05 – Neurology News Minute 9:15 – Safety, tolerability, and drug-drug interaction considerations for bexicaserin 11:20 – Lundbeck's strategy across rare and severe neurological disorders The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis Semaglutide Linked to Improved Neurological Outcomes in Large Vessel Occlusion Without IV Thrombolysis FDA Approves Generic Glatiramer Acetate Injection for Multiple Sclerosis Treatment Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Clinical Advances and Unanswered Questions in Narcolepsy," Lindsay McCullough, MD, discusses how clinical understanding of narcolepsy has evolved, where major diagnostic and treatment advances have occurred, and where important gaps remain. McCullough, assistant professor of medicine and associate program director for the sleep medicine fellowship at Rush University, reflects on progress in defining narcolepsy subtypes, the growing role of orexin biology, and how recent research in 2025 has reshaped conversations around disease-modifying approaches. The discussion also explores emerging links between sleep disorders and neurodegenerative disease, common misconceptions that continue to delay diagnosis, and how clinician education can improve recognition, safety, and long-term management of patients with narcolepsy. Looking for more Sleep Disorder discussion? Check out the NeurologyLive® Sleep Disorder clinical focus page. Episode Breakdown: 1:05 – Advances and remaining gaps in the clinical understanding of narcolepsy 2:30 – How narcolepsy care and research meaningfully evolved throughout 2025 4:50 – Sleep disorders, neurodegeneration, and what clinicians should watch for 6:50 – Neurology News Minute 8:50 – Persistent myths that delay diagnosis and affect clinical decision-making 12:30 – How lived experience shapes holistic, patient-centered narcolepsy care The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Mood, Behavior, and Quality of Life in Parkinson Disease," Sneha Mantri, MD, MS, Chief Medical Officer at the Parkinson’s Foundation, discusses how mood and behavioral symptoms shape the lived experience of people with Parkinson disease across the disease course. Mantri, a practicing movement disorders specialist with extensive training and experience, explains why depression and anxiety often precede motor symptoms, how these issues evolve with cognitive change, and why they remain key drivers of quality of life. Mantri reviews commonly used screening tools – including the PHQ-2/9, Geriatric Depression Scale, GAD-7, and emerging measures like the HOPE questionnaire – emphasizing their role in opening deeper clinical conversations. She also highlights Parkinson’s Foundation initiatives that support both clinicians and patients, from PD Health at Home programming to team-based care models. The conversation concludes with ongoing challenges, including cultural barriers to mental health care, access limitations, and the continued need for true mental health parity in Parkinson disease management. Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page. Episode Breakdown: 1:10 – How mood and behavior symptoms shape Parkinson disease quality of life 5:30 – How conversations about mental health in Parkinson disease have evolved 9:25 – Screening tools and practical assessment strategies for mood and anxiety 13:40 – Neurology News Minute 15:50 – Foundation and community initiatives supporting mood and behavior care 19:50 – Remaining gaps, cultural barriers, and mental health parity challenges The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease Gene Therapy ETX101 Demonstrates Significant Effects on Seizure Reduction, Neurodevelopmental Outcomes in POLARIS Phase 1/2 Program FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Understanding Variability in Infantile Spasms Care," Christina Briscoe, MD, epileptologist at Boston Children’s Hospital, discusses new multi-center findings on current treatment practices for infantile epileptic spasms syndrome (IESS). Briscoe outlines why first- and second-line therapies remain largely standardized, yet significant variability emerges once hormonal therapy and vigabatrin fail. She details the evidence gaps driving inconsistent third-line and fourth-line decision-making, including limited clinical trial data, uneven access to ketogenic diet programs and epilepsy surgery, and historically low industry investment in infant-specific trials. Additional discussion focuses on ongoing research from the Pediatric Epilepsy Research Consortium, national and global comparisons in treatment pathways, barriers to study scalability in rare pediatric epilepsies, and the practical challenges of implementing timely diagnosis and standardized care across diverse healthcare settings. Briscoe also highlights under-recognized issues such as incorporation of ketogenic diet and early surgical evaluation into treatment pathways, and emphasizes the need for broader infrastructure, funding, and multi-center collaboration to improve outcomes for children with IESS. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:05 – Origins of the study, need to pursue more standardized care in IESS 4:40 – Reasons behind treatment variability after first and second-line options 8:00 – What research is needed to guide sequencing and standardize care 12:05 – Neurology News Minute 14:30 – What makes IESS studies difficult and how infrastructure can improve 18:50 – Lesser-discussed gaps, including ketogenic diet and surgical evaluation The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "NEALS 2025: Takeaways That Matter for ALS Care," ALS experts Jinsy Andrews, MD, MSc, and James Berry, MD, MPH, reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for ALS. They discuss format changes that elevated lightning science, the expanding gene therapy pipeline, and a growing slate of NEALS-affiliated trials. The conversation highlights updates from the HEALEY Platform Trial, the MY-MATCH biomarker-guided precision trial, SOD1 program data, and new antisense and viral vector therapies aimed at sporadic ALS. They also explore the impact of Act for ALS on trial access, the ALL ALS biospecimen repository, and NIH-supported expanded access cohorts. The discussion closes with insights on combination therapy strategies, genetic subtypes, presymptomatic enrollment, and how new collaborations, digital endpoints, and infrastructure advances are shaping momentum heading into 2026. Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page. Episode Breakdown: 1:05 – Reflections on meeting highlights and NEALS rebranding into a global network 5:00 – Notable NEALS-affiliated trials and promising new mechanisms in ALS care 12:45 – Combination therapy strategies and future approaches in ALS research 15:20 – Neurology News Minute 18:00 – Expanding clinical trial access for rare and genetic ALS subtypes 22:10 – Building momentum and expectations for the 2026 NEALS Annual Meeting The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency Supplemental New Drug Application Submitted for AXS-05 as Treatment for Alzheimer Disease Agitation BTK Inhibitor Fenebrutinib Meets Primary End Points in Phase 3 Trials for Both Relapsing and Primary Progressive MS  Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. Following the 2025 Alzheimer's Association International Conference (AAIC), Rebecca Edelmayer, PhD, outlines the Alzheimer’s Association’s first clinical practice guidelines for using blood-based biomarkers (BBMs) in the diagnostic workup of suspected Alzheimer’s disease within specialized care. She explains the guideline mission, how tests were evaluated for accuracy, and when BBMs should serve as triage versus confirmatory tools relative to CSF and PET. Edelmayer details current scope limits (cognitively impaired patients in specialty settings), cautions against overextending to primary care or unimpaired populations, and previews the education roll-out—executive summaries, micro-learning modules, and shared decision-making resources. She closes with research priorities: stronger peer-reviewed reporting, broader validation across diverse populations and settings, and building an equitable pathway that leverages BBMs to speed accurate diagnosis and treatment access. Looking for more Alzheimer & dementia discussion? Check out the NeurologyLive® Alzheimer & dementia clinical focus page. Episode Breakdown: 1:05 – Understanding the purpose and mission behind new blood-based biomarker guidelines 2:05 – Key recommendations and defining triage vs confirmatory blood-based biomarker use 3:15 – Clinical precautions and where blood-based biomarkers are appropriate today 5:30 – Neurology News Minute 7:45 – Educating clinicians on implementing BBMs in specialty care 10:15 – Research priorities to strengthen evidence and ensure equity The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease B-Cell Modulator Obexelimab Shows Pronounced Relapse Reduction in Phase 2 MoonStone Trial Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Building Safer, Smarter, and More Personalized Epilepsy Care," Orrin Devinsky, MD, discusses major areas of progress and ongoing challenges in epilepsy care. Devinsky, a professor in the departments of neurology, neurosurgery, and psychiatry at NYU Grossman School of Medicine, reflects on how the treatment landscape has evolved in recent years, including advances in medication, awareness of SUDEP, and patient counseling. Devinsky also weighs in on the current treatment hierarchy for antiepileptic drugs and whether first-line therapeutic strategies should change. Additional discussion touches on the state of gene therapy development, the need for greater research in disease prevention, the implications of GLP/GIP agents in neurological care, and how neurodevelopmental management is advancing for pediatric patients with epilepsy. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 0:55 – How epilepsy care has evolved and where progress has been made 5:30 – Whether first-line therapy choices for epilepsy should be re-evaluated 8:35 – Why gene therapy progress has been slower than expected in epilepsy 12:05 – Neurology News Minute 14:10 – What areas of epilepsy research deserve greater attention and funding 17:10 – How GLP/GIP agents could intersect with neurological and epilepsy care 20:00 – How clinicians can better address neurodevelopmental challenges in patients with epilepsy The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Neflamapimod Advances to Phase 3 Trial in Dementia With Lewy Bodies After Positive RewinD-LB Results FDA Delays Review Deadline for Hunter Syndrome Agent Tividenofusp Alfa FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "ECTRIMS 2025 Meeting Highlights and Clinical Takeaways," Daniel Ontaneda, MD, PhD, neurologist at Cleveland Clinic’s Mellen Center for MS, shared his reflections from the 2025 ECTRIMS Congress, held September 24-26, in Barcelona, Spain. He discussed the significance of the updated MS diagnostic criteria, which generated immediate research applications and clinician discussion early in the meeting. Ontaneda also highlighted the growing emphasis on precision medicine and individualized treatment approaches, including extended-interval dosing strategies for B-cell therapies. In addition, he reviewed new therapeutic developments such as BTK inhibitors, CAR-T therapies, and remyelination research, noting both promising and disappointing data. Finally, he spoke on how ECTRIMS continues to expand beyond MS, with more presentations dedicated to NMOSD, MOGAD, and other autoimmune neurological conditions, reflecting the evolving landscape of neuroimmunology. Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® Multiple Sclerosis clinical focus page. Episode Breakdown: 1:00 – Overall impressions of ECTRIMS 2025, highlighting diagnostic updates, precision medicine, and late-breaking trial results 4:10 – Expanding focus on individualized care, especially interval-adjusted dosing strategies for B-cell therapies 7:50 – Neurology News Minute 9:50 – Insights on emerging therapeutic approaches including BTK inhibitors, CAR-T therapies, and remyelination strategies 14:35 – Growing attention toward NMOSD, MOGAD, and other autoimmune conditions within neuroimmunology discussions The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Rethinking Parkinson’s Care: Prevention, Equity, and Access to Treatment," Michael Okun, MD, neurologist, author of The Parkinson Plan, and medical advisor for the Parkinson’s Foundation, discusses the urgent need for global access to levodopa, the gold-standard treatment for Parkinson disease. He outlines the consequences of delayed or unavailable treatment worldwide, including worsening outcomes and unnecessary disability. Okun highlights lessons from global HIV drug distribution that can inform equitable levodopa access, emphasizing the importance of tailoring strategies to local economies and healthcare systems. Additionally, he breaks down key components of The Parkinson Plan, including prevention, research priorities, amplifying patient and caregiver voices, and rethinking care models to better address the world’s fastest growing neurodegenerative disorder. Finally, he explains how the book can serve as a resource not only for clinicians, but also for patients, families, and policymakers. Looking for more Movement disorders discussion? Check out the NeurologyLive® Movement disorders clinical focus page. Episode Breakdown: 1:00 – Consequences of delayed or unavailable levodopa treatment for patients worldwide 2:40 – How universal levodopa access could change care in low-resource settings 5:15 – Lessons from global HIV drug distribution for equitable levodopa delivery 7:00 – Neurology News Network 8:35 – Key pillars of The Parkinson Plan and rethinking Parkinson’s care models The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this special edition of Mind Moments, Patricia Pozo-Rosich, MD, PhD, head of the neurology department at Vall d’Hebron University Hospital, discussed the recent FDA approval of fremanezumab (Ajovy) for pediatric migraine prevention. As a study author on the pivotal phase 3 SPACE trial (NCT03539393), Dr. Pozo-Rosich reflected on the significance of having a proven therapeutic option in a population where placebo responses and lack of evidence have long complicated care. She provided insights on how the trial was designed and the challenges of running pediatric studies, particularly in adolescents. Additionally, she highlighted broader implications for migraine research, including efforts to reduce placebo effects, the role of CGRP pathway inhibition in younger patients, and the future promise of emerging targets such as PACAP antagonists and new toxin formulations. For more of NeurologyLive's coverage of fremanezumab's expanded indication in pediatric migraine, head here: FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine Episode Breakdown: 1:10 – Initial reaction to fremanezumab approval and significant for pediatric migraine care 6:05 – Major clinical insights and takeaways from phase 3 SPACE trial 10:20 – Challenges in pediatric migraine trials and addressing high placebo responses 15:10 – Future directions in migraine therapy, including PACAP-targeting drugs and novel approaches Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne," Barry Byrne, MD, chief medical advisor at the Muscular Dystrophy Association and director of the Powell Gene Therapy Center at the University of Florida, discusses newly published consensus guidelines from the MDA and Parent Project Muscular Dystrophy on the safe delivery and monitoring of gene therapy in Duchenne muscular dystrophy (DMD). Byrne explains the rationale behind convening a global panel of experts, emphasizing the need for standardized practices in patient selection, administration, and follow-up care as gene therapy becomes more widely available. He highlights the importance of expanded multidisciplinary teams—including hematology, cardiology, nephrology, and immunology—in managing immune-related safety concerns, with particular attention to monitoring liver inflammation and emerging strategies such as rapamycin use. In addition, Byrne outlines how these guidelines address real-world challenges around access, including geographic barriers, language considerations, and financial constraints, while underscoring their role in shaping future gene therapy approaches as additional therapies move through development. Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page. Episode Breakdown: 1:00 – Why consensus guidelines were needed for gene therapy in DMD 2:10 – Top-line clinical considerations from the published recommendations 4:30 – Protocols for monitoring and managing adverse events, especially liver toxicity 6:30 – Neurology News Network 8:30 – Addressing health equity, language access, and financial barriers in gene therapy care 12:00 – How these recommendations may shape the future of DMD treatment The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Efgartigimod Aims to Become First Therapy for Seronegative Generalized Myasthenia Gravis Following Positive Phase 3 Data FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease Eisai Submits sBLA for Weekly Subcutaneous Lecanemab as Starting Dose Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care," Danielle Andrade, MD, MSc, adult neurologist at the University of Toronto and co-chair of the ILAE Transition Task Force, discussed the critical process of moving pediatric patients with epilepsy into adult care. She highlighted findings from the task force’s global survey on transition practices, revealing major differences across regions. Andrade also shared important considerations for students with epilepsy entering college, including lifestyle management and the “perfect storm” of seizure triggers like sleep deprivation, alcohol, and medication adherence. She spoke on the vital role of reproductive health discussions, the utility of readiness questionnaires, and the challenges of coordinating multi-specialty care. Finally, Andrade underscored the importance of clear communication between pediatric and adult neurologists, as well as the need for stronger guidelines and education worldwide. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:00 – Global survey findings on epilepsy transition of care 2:10 – Key considerations for students with epilepsy entering college 3:50 – Ensuring continuity of care during transition into adulthood 5:45 – Neurology News Minute 7:30 – Common challenges and strategies to overcome them 9:30 – Final thoughts on back-to-school care and global survey insights The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Ianalumab Meets Primary End Points in Phase 3 NEPTUNUS Trials of Sjögren’s Disease Praxis’ Vormatrigine Shows Significant Ability to Reduce Seizure Incidence in Phase 2 RADIANT Study FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management" Alex Dessy, MD, clinical assistant professor in movement disorders at Jefferson Health, shares a comprehensive look at modern-day care strategies for patients with Parkinson disease and other movement disorders. Dessy discusses the foundational role of detailed history-taking, exam-based observation, and phenomenology in diagnosing complex conditions, along with the growing utility of genetic and imaging tools. She also explains the challenges of managing nonmotor symptoms—like sleep disturbance, fatigue, and constipation—and how lifestyle strategies and interdisciplinary collaboration are often as vital as medication. Lastly, she emphasizes the importance of clear and compassionate communication with patients and families as neurology becomes increasingly therapeutic. Looking for more Movement disorders discussion? Check out the NeurologyLive® Movement disorders clinical focus page. Episode Breakdown: 1:00 – How movement disorder diagnosis is approached through history, physical exam, and phenomenology 4:05 – What makes certain movement disorder cases complex and how diagnostics like genetics and imaging are used 6:20 – Neurology News Minute 8:45 – How nonmotor symptoms in Parkinson’s (fatigue, constipation, sleep) are managed with lifestyle strategies 12:30 – Approaching therapeutic communication and expectation-setting with patients and families The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Eisai Showcases Promising 4-Year Data for Alzheimer Therapy Lecanemab at AAIC 2025 IHL-42X to Enter Phase 3 Trials for Obstructive Sleep Apnea Following Positive Phase 2 Data FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer’s Care" John Sims, MD, head of medical development for donanemab at Eli Lilly and Company, joins NeurologyLive to discuss the recently updated label for donanemab (Kisulna), an anti-amyloid Alzheimer disease (AD) therapy. Sims breaks down the key safety data from the TRAILBLAZER-ALZ-6 study (NCT05738486) that led to a newly approved titration-based dosing regimen aimed at minimizing ARIA risk. He outlines considerations for clinicians treating patients with early-stage AD, including genotype-based stratification, ARIA severity patterns, and implications for prescribing and patient counseling. Furthermore, Sims also shares takeaways about donanemab’s clinical impact and how the results may shape the future of anti-amyloid therapy development and AD care. Looking for more dementia and Alzheimer disease discussion? Check out the NeurologyLive® Dementia and Alzheimer disease clinical focus page. Episode Breakdown: 1:00 – Overview of the new donanemab dosing regimen and its goal to reduce ARIA risk 2:30 – Rationale behind the four different dosing strategies tested in Trailblazer-ALZ-6 6:00 – What clinicians should know about patient risk and genotype testing 8:00 – Neurology News Minute 10:10 – Clinical implications of the updated label, including risk-benefit conversations 13:45 – Surprising results from the trial, particularly for APOE4 homozygous patients The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies FDA Shuts Down Sarepta's Distribution of Gene Therapy Elevidys Following Patient Deaths AD109 Meets End Points in Phase 3 LunAIRo Trial, Eyeing FDA Submission for Obstructive Sleep Apnea Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.